

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED
大健康國際集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2211)

FORECASTED INTERIM RESULTS – SIGNIFICANT DECREASE IN LOSS

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, the interim results of the Group is expected to record a significant decrease in loss for the six months ended 31 December 2018 as compared to the loss in the corresponding period in 2017.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

This announcement is made by Universal Health International Group Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Directors**”) of the Company (the “**Board**”) wishes to inform the shareholders and potential investors of the Company that, based on the preliminary review of the unaudited consolidated management accounts of the Group and the current available information to the Board, the interim results of the Group is expected to record a significant decrease in loss for the six months ended 31 December 2018 (the “**Period**”) as compared to the loss recorded in the corresponding period in 2017. Details of which will be disclosed in the results announcement to be published in late February 2019.

The Board considers that the expected significant decrease in loss recorded for the Period as compared to the loss in the corresponding period in 2017 was mainly due to the following factors:

- (i) the Group has made an analysis on the impact of the macro and industrial economic environment and performed an impairment assessment on goodwill. Based on that the Group made a provision for impairment loss on goodwill (approximately RMB288 million) arising on the acquisition of retail and distribution businesses in prior years in the corresponding period in 2017, while there is no provision for impairment loss on goodwill made during the Period;
- (ii) marketing expenses and administrative expenses of the Group during the Period are lower than the corresponding period in 2017.

As the Group is expected to record a significant decrease in loss for the Period as compared to the loss in the corresponding period in 2017, the Board is of the view that the overall financial position of the Group is healthy. The Group has proactively facilitated its strategic transformation, promoted the development of the partnership mechanism, constructed the “Universal Health+” platform and diversified its breakthrough models; and timely improved the share option scheme to maintain our competitiveness. Thus, the Board holds an optimistic view for the long term outlook of the Group.

Since the unaudited interim results of the Group for the Period have not yet been finalized and have not been reviewed by the audit committee of the Company, the information contained in this announcement is only based on the current available information and the preliminary unaudited consolidated management accounts of the Group, which are subject to finalization and, if any, adjustment. It is expected that the unaudited interim results of the Group for the Period will be announced in late February 2019.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Universal Health International Group Holding Limited
Jin Dongtao
Chairman

Hong Kong, 30 January 2019

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Jin Dongtao, Mr. Jin Dongkun, Mr. Zhao Zehua and Mr. Sun Libo and three independent non-executive directors, namely, Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Zou Haiyan.